(MedPage Today) — CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell carcinoma (HNSCC), according…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115840
Author :
Publish date : 2025-06-01 21:35:00
Copyright for syndicated content belongs to the linked Source.
